SEMA3A and atopic eczema: sema3A replacement was reported to normalize the hyper-innervation in atopic dermatitis, resulting in suppression of itching suggesting sema3A to be a potential therapeutic strategy in a wide spectrum of immune-mediated inflammatory diseases (18–20).